Progression-free survival and safety at 3.5 years of follow-up: results from the randomized phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer – a plain language summary

Antonio González-Martín1 Medical Oncology Department, Cancer Center Clínica Universidad de Navarra, Madrid, Program in Solid Tumours, CIMA, Pamplona, & Grupo Español de Investigación en Cáncer de Ovario (GEICO), Madrid, Spain

Bhavana Pothuri2 Gynecologic Oncology Group (GOG Foundation), NYU Langone Health, Department of Obstetrics & Gynecology, Perlmutter Cancer Center, New York, NY, USA

Ignace Vergote3 Belgium & Luxembourg Gynaecological Oncology Group (BGOG), Department of Gynaecology & Obstetrics, Division of Gynaecological Oncology, University Hospitals Leuven, Leuven Cancer Institute, Leuven, Belgium, European Union

Whitney Graybill4 GOG, Gynecologic Oncology, Medical University of South Carolina, Charleston, SC, USA

Domenica Lorusso5 Multicentre Italian Trials in Ovarian Cancer & Gynecologic Malignancies (MITO), Fondazione Policlinico Gemelli IRCCS & Catholic University of Sacred Heart, Rome, Italy, when the study was conducted; present affiliation Humanitas San Pio X, Milan, Humanitas University, Rozzano, Italy

Colleen C McCormick6 GOG, Legacy Medical Group Gynecologic Oncology, Portland, OR, USA

Gilles Freyer7 Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO), HCL Cancer Institute, Department of Medical Oncology, Lyon University, Lyon, France

Floor Backes8 Division of Gynecologic Oncology, Ohio State University, Columbus, OH, USA

Florian Heitz9 AGO Study Group & the Department for Gynaecology & Gynaecologic Oncology, Kliniken Essen-Mitte, Essen, & Charité - Universitätsmedizin Berlin, Humboldt- Universität zu Berlin, Berlin Institute of Health, Department of Gynaecology, Berlin, Germany

Andrés Redondo10 GEICO, Department of Medical Oncology, Hospital Universitario La Paz–IdiPAZ, Madrid, Spain

Richard G Moore11 Division of Gynecologic Oncology, Wilmot Cancer Institute, Department of Obstetrics & Gynecology, University of Rochester, Rochester, NY, USA

Christof Vulsteke12 BGOG, Department of Medical Oncology & Hematology, AZ Maria Middelares, Gent, & Department of Molecular Imaging, Pathology, Radiotherapy & Oncology, Center for Oncological Research, Antwerp University, Antwerp, Belgium

Roisin E O'Cearbhaill13 GOG, Gynecologic Medical Oncology, Memorial Sloan Kettering Cancer Center, & Department of Medicine, Weill Cornell Medical College, New York, NY, USA

Izabela A Malinowska14 GSK, Middlesex, UK

Luda Shtessel14 GSK, Middlesex, UK

Natalie Compton14 GSK, Middlesex, UK

Mansoor R Mirza15 Department of Oncology, Rigshospitalet–Copenhagen University Hospital & Nordic Society of Gynaecological Oncology, Copenhagen, Denmark

Bradley J Monk16 HonorHealth Research Institute, University of Arizona College of Medicine, Phoenix Creighton University, Phoenix, AZ, USA, when the study was conducted; present affiliation GOG Foundation; Florida Cancer Specialists & Research Institute, West Palm Beach, FL, USA

show all

Progression-free survival and safety at 3.5 years of follow-up: results from the randomized phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer – a plain language summary

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Progression-free survival and safety at 3.5 years of follow-up: results from the randomized phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer – a plain language summary

Figures & data

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date